C

    Cognition Therapeutics Inc (CGTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.03
    +0.01 (+0.98%)

    Market Cap: $97.00M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(14/21)
    Avg Surprise
    -201.12%
    Streak
    5 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.07
    Range$-0.07 - $-0.06
    3 analysts
    EPS RevisionsNo revisions (7d)
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.07-9.9%
    60d ago$-0.07-8.7%
    30d ago$-0.07-8.7%
    7d ago$-0.07-4.9%
    Current$-0.07
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.22 - $-0.00
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.07---
    Jun 26
    		$-0.04$-0.06+33.33%Beat+63.6%
    Mar 26
    		$-0.05$-0.07+28.57%Beat+64.3%
    Dec 25
    		$-0.02N/A+74.19%Beat+89.4%
    Sep 25
    		$-0.06$-0.11+45.45%Beat+76.0%
    Jun 25
    		$-0.11$-0.12+8.33%Beat+38.9%
    Mar 25
    		$-0.14$-0.11-27.27%Miss+48.1%
    Dec 24
    		$-0.19$-0.17-11.00%Miss+30.1%
    Sep 24
    		$-0.25$-0.21-19.05%Miss-13.6%
    Jun 24
    		$-0.18$-0.23+21.74%Beat-12.5%
    Mar 24
    		$-0.27$-0.24-12.50%Miss-28.6%
    Dec 23
    		$-0.27$-0.34+20.59%Beat-35.0%
    Sep 23
    		$-0.22$-0.29+24.14%Beat+24.1%
    Jun 23
    		$-0.16$-0.21+23.81%Beat+36.0%
    Mar 23
    		$-0.21$-0.18-16.67%Miss-23.5%
    Dec 22
    		$-0.20$-0.30+33.33%Beat+98.3%
    Sep 22
    		$-0.29$-0.32+9.38%Beat-61.1%
    Jun 22
    		$-0.25$-0.32+21.88%Beat+56.9%
    Mar 22
    		$-0.17$-0.29+41.38%Beat+96.4%
    Dec 21
    		$-11.74$-0.26-4415.38%Miss-613.7%
    Sep 21
    		$-0.18N/A+68.42%Beat+96.8%
    Jun 21
    		$-0.58$-0.21-176.19%Miss+92.3%
    Mar 21
    		$-4.77$0.00N/AMiss-
    Dec 20
    		$-1.64$0.00N/AMiss-
    Mar 20
    		$-5.59$0.00N/AMiss-
    Dec 19
    		$-7.58$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-6.06EV/EBITDA-0.44x
    Price/FCF-5.28xFCF Yield-18.94%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-83.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio7.03xQuick Ratio7.03x
    Trading Statistics
    Beta1.78Avg Volume544.15K
    52-Week High$2.6752-Week Low$0.55

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.01
    SMA 20$1.03
    SMA 50$1.04
    SMA 200$1.20
    EMA 10$1.02
    EMA 20$1.02
    EMA 50$1.05
    EMA 200$1.13

    MACD

    Line: 0.00Signal: -0.01Hist: 0.01

    ADX

    ADX: 12.1+DI: 19.4-DI: 20.3

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down8.0
    PSAR$1.07

    Bollinger Bands

    Upper Band$1.11
    Lower Band$0.95
    %B Position1579%(Upper)
    Band Width0.52

    RSI (14-Day)

    Neutral
    51.3

    Momentum Oscillators

    Stoch %K65.3
    Stoch %D63.7
    Williams %R-33.4
    ROC (10d)1.0%
    Momentum0.01
    CCI (20d)10.4
    MFI (14d)38.7

    Volatility Measures

    ATR (14d)$0.06(6.0%)
    StdDev (20d)0.04
    Hist Vol65.8%(High)

    Volume Flow

    VWAP$1.03
    OBV385.0M
    AD Line-197.6M
    CMF (20d)-0.029

    Volume Metrics

    Avg Vol (20d)555.1K
    Vol Ratio0.5x
    VWMA (20d)$1.04

    Pivot Points

    R3$1.10
    R2$1.09
    R1$1.05
    Pivot Point$1.04
    S1$1.00
    S2$0.99
    S3$0.95

    Advanced Oscillators

    TSI0.03
    Ultimate Osc55.6
    KST17.06

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$250,000$0$0$0$372,000$0
    Cost of Revenue$0$0$61,000$0$0$0$71,000$0$0$0$66,000$0
    Gross Profit$0$0$-61,000$0$0$0$-71,000$0$0$0$306,000$0
    Operating Expenses$7.74M$8.82M$13.67M$6.38M$13.98M$13.78M$10.72M$14.46M$14.68M$14.10M$15.19M$14.74M
    R&D$5.10M$6.12M$11.15M$3.77M$11.48M$10.79M$8.15M$11.39M$11.58M$10.55M$11.60M$11.67M
    SG&A$2.64M$2.70M$2.52M$2.60M$2.50M$2.99M$2.57M$3.07M$3.10M$3.55M$3.59M$3.08M
    Operating Income$-7,738,000$-8,817,000$-13,671,000$-6,375,000$-13,978,000$-13,775,000$-10,723,000$-14,463,000$-14,678,000$-14,102,000$-15,189,000$-14,745,000
    Interest Income$-3,000$-5,000$-5,000$0$-3,000$-5,000$-5,000$-3,000$-7,000$-10,000$0$-2,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-3,935,000$-4,575,000$-3,348,000$-4,930,000$-6,737,000$-8,485,000$-7,847,000$-9,940,000$-7,048,000$-9,161,000$-8,150,000$-6,751,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,935,000$-4,575,000$-3,343,000$-4,930,000$-6,737,000$-8,485,000$-7,842,000$-9,937,000$-7,041,000$-9,151,000$-8,141,000$-6,749,000
    EBITDA$-3,877,000$-4,502,000$-3,282,000$-4,869,000$-6,673,000$-8,435,000$-7,771,000$-9,867,000$-6,974,000$-9,093,000$-8,075,000$-6,684,000
    EBIT$-3,932,000$-4,570,000$-3,343,000$-4,930,000$-6,734,000$-8,480,000$-7,842,000$-9,937,000$-7,041,000$-9,151,000$-8,141,000$-6,749,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CGTX

    News

    HC Wainwright Has Bullish Estimate for CGTX Q3 Earnings

    HC Wainwright has increased its Q3 2026 EPS estimate for Cognition Therapeutics (NASDAQ:CGTX) to a loss of $0.06 per share from a previous estimate of a $0.07 loss, maintaining a "Buy" rating. This update comes after Cognition Therapeutics reported a Q2 loss of $0.04 per share, surpassing analyst estimates. The stock currently holds a "Moderate Buy" consensus rating with an average price target of $3.33, though analyst opinions are mixed.

    MarketBeat•8/17/26•
    Bullish

    CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets

    Brookline Capital Markets has increased its FY2026 EPS estimate for Cognition Therapeutics (NASDAQ:CGTX) to a loss of $0.42 per share, an improvement from their previous forecast of a $0.44 loss, though still below the consensus of a $0.34 loss. The company recently reported a quarterly loss of $0.04 per share, surpassing analyst expectations. Despite a slight dip in share price, analysts maintain a "Moderate Buy" rating with an average target of $3.33, and institutional investors hold a significant stake in the company.

    MarketBeat•8/12/26•
    Somewhat-Bullish

    Cognition Therapeutics Inc (CGTX) Stock News Today

    This article provides an overview of Cognition Therapeutics Inc (CGTX) stock information, including its current price, market capitalization, and a note that more news is coming soon. It highlights where to find news, earnings, analyst ratings, and key developments for the company.

    TradingKey•8/9/26•
    Neutral

    Cognition Therapeutics, Inc. (CGTX) stock price, news, quote and history

    This Yahoo Finance page provides comprehensive information on Cognition Therapeutics, Inc. (CGTX), including its current stock price, historical data, company overview, financial performance, and analyst ratings. CGTX is a clinical-stage biopharmaceutical company developing therapeutics for age-related degenerative diseases, with its lead candidate zervimesine in Phase 2 clinical studies for Alzheimer's and other neurological conditions. The stock was trading at 1.0676 USD after hours, with a market capitalization of 96.658M.

    Yahoo Finance UK•8/8/26•
    Neutral

    Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS

    Cognition Therapeutics (NASDAQ:CGTX) reported a quarterly loss of $0.04 per share, surpassing analysts' consensus estimate by $0.02. Following the earnings release, CGTX shares declined by $0.05 to $1.08. Institutional investors hold 43.35% of the stock, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $3.33.

    MarketBeat•8/8/26•
    Somewhat-Bullish

    Frequently Asked Questions About CGTX

    Does CGTX pay dividends?
    Cognition Therapeutics Inc (CGTX) does not currently pay a regular dividend.
    What is CGTX's market cap?
    Cognition Therapeutics Inc (CGTX) has a market capitalization of $97.00M with a current stock price of $1.03.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In